Carboplatin Other names: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)

Chemical formula: C₆H₁₂N₂O₄Pt  Molecular mass: 371.254 g/mol  PubChem compound: 38904

Therapeutic indications

Carboplatin is indicated for:

Small cell carcinoma of the lung

Population group: only adults (18 years old or older)

Carboplatin is indicated for the treatment of small cell carcinoma of the lung.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Advanced ovarian carcinoma of epithelial origin

Population group: women, only adults (18 years old or older)

Carboplatin is indicated for the treatment of:

  • Advanced ovarian carcinoma of epithelial origin in:
    • first line therapy
    • second line therapy, after other treatments have failed.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Carboplatin is contraindicated in the following cases:

Severe myelosuppression

Myelosuppression

Severe renal impairment (creatinine clearance of ≤30 ml per minute)

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Bleeding tumors

Haemorrhagic tumour

Yellow fever vaccines

Yellow fever vaccines

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2018: CARBOPLATIN Solution for infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈